← United States · Coverage record
US · SEC FORM 4
Voyager Therapeutics, Inc.
VYGR · Nasdaq · CIK 0001640266 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-02-23 · NEUROCRINE BIOSCIENCES INC.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 3,973,207
- Previous report
- 3,655,802
- Avg daily volume
- 618,059
- Days to cover
- 6.4
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2023-02-23 | NEUROCRINE BIOSCIENCES INC | Purchase (P) | Common Stock | 4,395,588 | USD 8.88 | USD 39,032,821 | SEC filing ↗ |
| 2022-06-23 | EcoR1 Capital, LLC | Purchase (P) | Common Stock | 376,000 | USD 5.66 | USD 2,128,160 | SEC filing ↗ |
| 2022-06-21 | EcoR1 Capital, LLC | Purchase (P) | Common Stock | 101,400 | USD 5.28 | USD 535,392 | SEC filing ↗ |
Form 4 evidence
17 transaction lines in the latest 365-day window; 152 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred | Sale (S) | Common Stock | 11,511 | USD 3.87 | USD 44,548 | SEC filing ↗ |
| 2026-04-01 | Shiferman Gregory L. | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-24 | Swartz Robin | Sale (S) | Common Stock | 6,458 | USD 3.77 | USD 24,347 | SEC filing ↗ |
Show recent Form 4 evidence (17 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred | Sale (S) | Common Stock | 11,511 | USD 3.87 | USD 44,548 | SEC filing ↗ |
| 2026-04-01 | Shiferman Gregory L. | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-24 | Swartz Robin | Sale (S) | Common Stock | 6,458 | USD 3.77 | USD 24,347 | SEC filing ↗ |
| 2026-02-24 | Sandrock Alfred | Sale (S) | Common Stock | 14,197 | USD 3.79 | USD 53,807 | SEC filing ↗ |
| 2026-02-24 | Jorgensen Nathan D. | Sale (S) | Common Stock | 4,668 | USD 3.77 | USD 17,598 | SEC filing ↗ |
| 2026-02-24 | Carter Todd Alfred | Sale (S) | Common Stock | 4,174 | USD 3.76 | USD 15,694 | SEC filing ↗ |
| 2026-02-18 | Swartz Robin | Sale (S) | Common Stock | 3,882 | USD 3.44 | USD 13,354 | SEC filing ↗ |
| 2026-02-18 | Sandrock Alfred | Sale (S) | Common Stock | 11,732 | USD 3.41 | USD 40,006 | SEC filing ↗ |
| 2026-02-18 | Carter Todd Alfred | Sale (S) | Common Stock | 3,301 | USD 3.44 | USD 11,355 | SEC filing ↗ |
| 2026-02-10 | Swartz Robin | Sale (S) | Common Stock | 4,569 | USD 3.85 | USD 17,591 | SEC filing ↗ |
| 2026-02-10 | Sandrock Alfred | Sale (S) | Common Stock | 12,192 | USD 3.78 | USD 46,086 | SEC filing ↗ |
| 2026-02-10 | Carter Todd Alfred | Sale (S) | Common Stock | 3,525 | USD 3.85 | USD 13,571 | SEC filing ↗ |
| 2026-02-06 | Swartz Robin | Award / grant (A) | Common Stock | 45,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-06 | Sandrock Alfred | Award / grant (A) | Common Stock | 86,250 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-06 | Jorgensen Nathan D. | Award / grant (A) | Common Stock | 32,250 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-06 | Ferguson Toby | Award / grant (A) | Common Stock | 45,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-06 | Carter Todd Alfred | Award / grant (A) | Common Stock | 33,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | VYGR |
| CIK | 0001640266 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 152 transaction lines from 2020-01-21 to 2026-04-02 3 P purchase lines · 101 S sale lines · 48 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.